Why this study matters

Stickler syndrome is an inherited connective-tissue condition that can affect the eyes, hearing, joints, and facial development. For many people and families living with Stickler syndrome, the most urgent eye-related concern is retinal detachment—a sight-threatening event in which the light-sensing retina separates from the back of the eye. Stickler syndrome is the most common cause of retinal detachment in children, making prevention a central goal of care.

Previous large studies in type 1 Stickler syndrome found that preventive retinal cryotherapy can substantially lower detachment risk. However, type 2 Stickler syndrome has lacked comparable evidence. Type 2 disease is genetically distinct from type 1, so it is important to establish whether a preventive approach works in this specific patient group rather than assuming results are identical.

A 2026 study in Ophthalmology addresses this evidence gap. It examined whether the Cambridge prophylactic cryotherapy protocol was associated with a lower risk of retinal detachment in a national cohort of people with genetically confirmed type 2 Stickler syndrome.

What is prophylactic cryotherapy?

Cryotherapy uses controlled freezing to create treatment spots in the far peripheral retina. In Stickler syndrome, the retina can be particularly vulnerable to tears and detachment. The purpose of preventive, or prophylactic, cryotherapy is to reinforce the peripheral retinal area and reduce the likelihood that a detachment will develop.

The study evaluated a standardized approach known as the Cambridge prophylactic cryotherapy protocol. Importantly, the publication assessed outcomes from this specific protocol; the abstract does not provide technical details of the treatment procedure itself.

A large genetically confirmed cohort

The investigators conducted a retrospective comparative case series involving 197 patients with genetically confirmed type 2 Stickler syndrome. They compared the time until retinal detachment occurred between people who received prophylactic cryotherapy and those who did not receive prophylaxis.

The main comparison included 85 people who received treatment in both eyes and 100 control participants who did not receive preventive treatment in either eye. The researchers also performed a matched analysis, designed to make the treatment and control groups more comparable. In addition, they examined a particularly important clinical situation: patients who had already experienced a retinal detachment in one eye. In this analysis, they compared eyes receiving preventive cryotherapy with untreated fellow eyes in a control group.

Key findings: lower detachment risk after prophylaxis

Across the main analysis, retinal detachment was more common among untreated participants. The bilateral control group had a 5.7-fold higher risk of retinal detachment than the bilateral prophylaxis group. This difference was statistically significant.

When the investigators matched participants between groups, the untreated group still had a higher risk: 3.3 times that of the matched prophylaxis group. While the confidence interval in this analysis was broader, the finding remained statistically significant.

The results were especially notable for people facing risk in their remaining seeing eye after a detachment had occurred in the other eye. In the unilateral analysis, the risk of retinal detachment in a second eye was 10.1 times higher in untreated controls than in the group receiving prophylactic cryotherapy. This comparison included 34 untreated controls and 12 people receiving unilateral prophylaxis.

Together, these results suggest that the Cambridge protocol may reduce the incidence of retinal detachment in type 2 Stickler syndrome, including in the high-risk setting of a prior detachment in the other eye.

Safety findings

Preventive treatment must balance potential benefit against potential harm. In this cohort, no patients experienced serious long-term adverse effects from prophylactic cryotherapy. The authors therefore concluded that the protocol appeared safe as well as effective within the population studied.

This finding is meaningful because Stickler syndrome often affects children and young adults, who may live for decades with the consequences of both the condition and any preventive eye procedure. Evidence that no serious long-term adverse effects were identified supports further consideration of prophylaxis in appropriate patients.

What this could mean for care

This study strengthens the evidence base for proactive retinal-detachment prevention in type 2 Stickler syndrome. It also reinforces the value of genetic confirmation: identifying the specific type of Stickler syndrome can help connect patients to evidence that is directly relevant to their condition.

For retinal specialists, the findings support discussion of standardized prophylactic cryotherapy as a strategy to lower detachment risk in type 2 Stickler syndrome. For families, the research highlights why ongoing retinal surveillance and timely specialist care remain essential, particularly after a detachment in one eye.

The study was retrospective, meaning it evaluated outcomes from patients who had already received care rather than assigning treatment prospectively. Even so, its national cohort, genetically confirmed diagnoses, matched analysis, and separate evaluation of second-eye risk provide important real-world evidence.

Looking ahead

The publication brings type 2 Stickler syndrome closer to the level of evidence previously available for type 1 disease. Future research can build on these results by examining long-term outcomes in additional cohorts and refining which patients may benefit most from preventive treatment.

Most importantly, this work shifts the focus from treating retinal detachment after it occurs toward reducing the chance that it occurs at all. For people with type 2 Stickler syndrome, that prevention-focused approach could have profound implications for preserving vision.